ABCELLERA BIOLOGICS (8QQ) - Total Liabilities
Based on the latest financial reports, ABCELLERA BIOLOGICS (8QQ) has total liabilities worth €411.56 Million EUR (≈ $481.15 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore investment intensity of ABCELLERA BIOLOGICS to see how much of total assets are deployed in long-term investments.
ABCELLERA BIOLOGICS - Total Liabilities Trend (2021–2025)
This chart illustrates how ABCELLERA BIOLOGICS's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 8QQ total assets.
ABCELLERA BIOLOGICS Competitors by Total Liabilities
The table below lists competitors of ABCELLERA BIOLOGICS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Denali Therapeutics Inc
NASDAQ:DNLI
|
USA | $322.78 Million |
|
HSBC Holdings PLC
LSE:HSBA
|
UK | GBX3.24 Trillion |
|
China Communications Construction Company Limited
F:CYY
|
Germany | €1.55 Trillion |
|
Craftsman Automation Limited
NSE:CRAFTSMAN
|
India | Rs-32.64 Billion |
|
Energix Renewable Energies Ltd
TA:ENRG
|
Israel | ILA10.61 Billion |
|
Hercules Capital Inc
NYSE:HTGC
|
USA | $2.22 Billion |
|
Huaneng Power International Inc
F:HUP1
|
Germany | €407.69 Billion |
|
China Southern Power Grid Energy Efficiency & Clean Energy Co Ltd
SHE:003035
|
China | CN¥15.37 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down ABCELLERA BIOLOGICS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ABCELLERA BIOLOGICS balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ABCELLERA BIOLOGICS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ABCELLERA BIOLOGICS (2021–2025)
The table below shows the annual total liabilities of ABCELLERA BIOLOGICS from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €390.05 Million ≈ $456.00 Million |
+28.11% |
| 2024-12-31 | €304.47 Million ≈ $355.96 Million |
-9.32% |
| 2023-12-31 | €335.78 Million ≈ $392.56 Million |
+9.15% |
| 2022-12-31 | €307.63 Million ≈ $359.65 Million |
+5.05% |
| 2021-12-31 | €292.84 Million ≈ $342.36 Million |
-- |
About ABCELLERA BIOLOGICS
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for… Read more